These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26219615)

  • 21. Targeting angiogenesis in advanced non-small cell lung cancer.
    Lammers PE; Horn L
    J Natl Compr Canc Netw; 2013 Oct; 11(10):1235-47. PubMed ID: 24142825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
    Rossi A; Maione P; Ferrara ML; Sacco PC; Schettino C; Bareschino MA; Gridelli C
    Curr Med Chem; 2009; 16(30):3919-30. PubMed ID: 19747132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer.
    Huang Y; Carbone DP
    Biochim Biophys Acta; 2015 Apr; 1855(2):193-201. PubMed ID: 25598052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
    Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
    Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nintedanib in non-small cell lung cancer: from preclinical to approval.
    Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
    Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?
    Herbst RS; Sandler AB
    Oncologist; 2004; 9 Suppl 1():19-26. PubMed ID: 15178812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting tumor neovasculature in non-small-cell lung cancer.
    Pallis AG; Syrigos KN
    Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of bevacizumab in non-small cell lung cancer: an update.
    Lauro S; Onesti CE; Righini R; Marchetti P
    Anticancer Res; 2014 Apr; 34(4):1537-45. PubMed ID: 24692680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anti-angiogenic agents of lung cancer].
    Wakuda K; Takahashi T
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):162-71. PubMed ID: 24743195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
    Yang K; Wang YJ; Chen XR; Chen HN
    Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
    Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK
    Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer.
    Roviello G; Francini E; Perrella A; Laera L; Mazzei MA; Guerrini S; Petrioli R
    Cancer Biol Ther; 2015; 16(12):1720-5. PubMed ID: 26418066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Targeted therapies in the treatment of non-small cell lung cancer].
    De Grève J; Decoster L; Van Meerbeek J; Vermeij J; Teugels E; Schallier D
    Bull Cancer; 2008 Mar; 95(3):358-64. PubMed ID: 18390417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model.
    Masuda C; Sugimoto M; Wakita D; Monnai M; Ishimaru C; Nakamura R; Kinoshita M; Yorozu K; Kurasawa M; Kondoh O; Yamamoto K
    Clin Exp Metastasis; 2020 Feb; 37(1):199-207. PubMed ID: 31768815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.
    Rodríguez Garzotto A; Díaz-García CV; Agudo-López A; Prieto García E; Ponce S; López-Martín JA; Paz-Ares L; Iglesias L; Agulló-Ortuño MT
    Med Oncol; 2016 Oct; 33(10):105. PubMed ID: 27568331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
    Ellis PM; Al-Saleh K
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer.
    Karayama M; Inui N; Kusagaya H; Suzuki S; Inoue Y; Enomoto N; Fujisawa T; Nakamura Y; Suda T
    Cancer Chemother Pharmacol; 2016 May; 77(5):1011-8. PubMed ID: 27034279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential of antiangiogenic therapy in non-small cell lung cancer.
    Giaccone G
    Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.